(HealthDay News) — For patients with heart failure with reduced ejection fraction and predominantly central sleep apnea, adaptive servo-ventilation does not improve outcome, according to a study published online September 1 in the New England Journal of Medicine to coincide with the annual European Society of Cardiology Congress, held from August 29 to September 2 in London.

Martin R. Cowie, MD, from Imperial College London, and colleagues examined the impact of adaptive servo-ventilation in a trial involving 1,325 patients with a left ventricular ejection fraction of ≤45%, apnea-hypopnea index (AHI) of ≥15 events per hour, and a predominance of central events. Patients were randomized to receive guideline-based medical treatment with adaptive servo-ventilation or guideline-based medical treatment alone.

The researchers found that at 12 months, the mean AHI was 6.6 events per hour in the adaptive servo-ventilation group. There was no significant between-group difference in the incidence of the primary end point (54.1% in the adaptive servo-ventilation group and 50.8% in the control group; hazard ratio, 1.13; 95% confidence interval, 0.97–1.13; P=0.10). The adaptive servo-ventilation group had significantly higher all-cause mortality and cardiovascular mortality than the control group.

“We found that in patients who had heart failure with a reduced ejection fraction and predominantly central sleep apnea, the addition of adaptive servo-ventilation to guideline-based medical treatment did not improve the outcome,” the authors write.

Several authors disclosed financial ties to pharmaceutical and medical device companies, including ResMed, which funded the study.

Full Text
More Information